PremiumThe FlyApollomics announces results from Phase 3 bridging trial of uproleselan Apollomics Inc trading resumes Apollomics Inc trading halted, volatility trading pause PremiumThe FlyApollomics Inc trading halted, news pending Apollomics announces approval, date for 1-for-100 reverse share split Apollomics presents Vebreltinib data in patients with NSCLC PremiumThe FlyApollomics announces approval of vebreltinib in China Apollomics presents vebreltinib data at AACR meeting Apollomics price target lowered to $5 from $17 at H.C. Wainwright